Results 141 to 150 of about 48,469 (263)

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. [PDF]

Hemasphere
Belada D, Gardner FP, de Oliveira AC, Sancho JM, Lomaia E, Wright D, Turgut M, Martynova E, Lázár Z, Anz B, Wang MC, Legiec W, Opat S, Pailden J, Peltier HM, Marturano E, Dean JP, Flinn IW.   +17 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Aggressive Recurrent Bilateral Chylothorax Secondary to Follicular Lymphoma in an HIV-Positive Patient: A Case Report and Clinical Implications. [PDF]

Cureus
Jagra AS, Ali R, Klukowicz A, Sharma HO, Miller R.   +4 more
europepmc   +1 more source

Diagnostic potential of B‐cell translocation gene 2 in IgA nephropathy: Insights from molecular mechanisms

Journal of Cell Communication and Signaling, Volume 20, Issue 3, September 2026.
Diagnostic value of BTG2 and its immunoregulatory mechanism in IgAN. This study reveals that BTG2 improves immune microenvironment dysregulation, attenuates inflammation, and reduces fibrosis by promoting the expansion of T follicular helper cells, inducing macrophage polarization toward an M2 anti‐inflammatory phenotype, and inhibiting the TGF‐β1 ...
Min Kou, Mo Dan, Juan Cheng, Sheng Ge, Ruimin Ren   +4 more
wiley   +1 more source

Chylous Ascites: A Rare Initial Presentation of High-Grade Follicular Lymphoma. [PDF]

Case Rep Oncol Med
Nada R, Gvajaia A, Raza A, Raji M.
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Concomitant recurrent follicular lymphoma and prostate adenocarcinoma detected during routine urologic follow-up: a rare case report. [PDF]

Ann Med Surg (Lond)
El Hussein M, Abdul Khalek J, Nasrallah OG, Layoun C, Khouzami R, Bachir BG.   +5 more
europepmc   +1 more source

Primary Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma With SQSTM1::ALK Fusion

Diagnostic Cytopathology, Volume 54, Issue 9, Page E216-E220, September 2026.
ABSTRACT Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare and aggressive variant of inflammatory myofibroblastic tumor (IMT) characterized by epithelioid morphology, atypical features, ALK rearrangements, and early metastatic potential.
Havva Gokce Terzioglu, Phillip McMullen, Güliz A. Barkan   +2 more
wiley   +1 more source

The role of <i>EZH2</i> dysregulation in the pathogenesis of B-cell lymphomas and its implications as a target therapy. [PDF]

Front Oncol
Candelaria M.
europepmc   +1 more source

Relative Dose Intensity and Survival Outcomes in Older Adults With Lymphoma: A Single‐Center Retrospective Analysis

Journal of General and Family Medicine, Volume 27, Issue 5, September 2026.
ABSTRACT Background Treatment intensity in older adults with lymphoma is often reduced because of frailty, comorbidities, and poor performance status (PS). Whether chronological age or delivered treatment intensity better predicts outcomes remains unclear.
Akira Mochizuki, Shotaro Hagiwara
wiley   +1 more source